Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) is a global leader in the design and manufacturing of innovative solutions for injectable drug administration systems. Headquartered in Exton, Pennsylvania, West collaborates closely with healthcare partners from concept to patient delivery, ensuring efficiency, reliability, and safety in packaging and delivery systems. The company operates through two main segments: Proprietary Products and Contract-Manufactured Products. Proprietary Products, contributing approximately 80% of total revenue, include elastomer-based packaging components such as stoppers, seals, and plungers, as well as non-glass containment solutions and auto-injectors for injectable drugs. The Contract-Manufactured Products segment, accounting for the remaining 20%, focuses on manufacturing components for drug-injection devices and healthcare diagnostic devices.
West's commitment to cutting-edge technology, quality systems, and global regulatory compliance has positioned it as a key supplier to the pharmaceutical, biotechnology, and generic drug industries. The company supports its customers through sales, manufacturing, and research and development locations across North and South America, Europe, Asia, and Australia.
In recent financial results, West reported a solid performance despite the expected decline in COVID-19 related sales. The second-quarter and third-quarter 2023 showed a decline in net sales for Proprietary Products primarily due to reduced pandemic-related demand. However, the Contract-Manufactured Products segment demonstrated strong growth, with net sales increasing significantly. For the full-year 2023, West experienced challenges with headwinds from lower pandemic-related sales but saw gains in high-value product components and devices, as well as contract manufacturing.
West continues to innovate, recently expanding its administration systems portfolio with the FDA-cleared Vial2Bag Advanced® 13mm admixture device, enhancing drug preparation and delivery options at the point-of-care. As the company celebrates its 100-year milestone, it remains focused on meeting customer demand and investing in high-value products and manufacturing capacity to fuel future growth.
For more detailed information about West's latest financial performance and strategic initiatives, visit the company's official website.
West Pharmaceutical Services (NYSE: WST) has announced its second-quarter 2025 dividend payment. The company's Board of Directors has approved a dividend of $0.21 per share, which will be paid on May 7, 2025, to shareholders of record as of April 30, 2025. West Pharmaceutical Services is recognized as a global leader in innovative solutions for injectable drug administration.
West Pharmaceutical Services (NYSE: WST) reported Q4 2024 results with net sales of $748.8 million, up 2.3% year-over-year, and organic net sales growth of 3.3%. Q4 reported-diluted EPS was $1.78, down 2.7%, while adjusted-diluted EPS was $1.82, down 0.5%.
The Proprietary Products segment saw Q4 net sales increase to $613.9 million with 4.5% organic growth, while Contract-Manufactured Products segment declined 2.5% to $134.9 million. High-Value Products represented 74% of Proprietary segment sales.
For full-year 2024, total net sales declined 1.9% to $2.893 billion, with adjusted-diluted EPS of $6.75, down 16.5%. The company's 2025 guidance projects net sales of $2.875-2.905 billion with organic growth of 2-3%, and adjusted-diluted EPS of $6.00-6.20.
West Pharmaceutical Services (NYSE: WST) has announced its upcoming fourth-quarter and full-year 2024 financial results release, scheduled for Thursday, February 13, 2025, before market opening. The company will host a conference call at 9:00 a.m. Eastern Time to discuss the results and business expectations.
Interested participants can access the live webcast through the company's Investor Relations website. To participate in the Q&A session, advance registration is required, after which participants will receive dial-in details and a unique PIN. A slide presentation will be available in the Investors section on the day of the call. The webcast replay will be accessible for approximately 90 days following the event.
West Pharmaceutical Services (NYSE: WST) has declared its first-quarter 2025 dividend. The Board of Directors approved a dividend payment of $0.21 per share, which will be distributed on February 11, 2025. Shareholders who are on record as of February 7, 2025, will be eligible to receive this dividend payment.
West Pharmaceutical Services (NYSE: WST) has announced the launch of Daikyo PLASCAP® Ready-to-Use Validated (RUV) closures in a new nested format at Pharmapack in Paris. The product, featuring multiple configurations, supports advanced therapies, particularly in cell and gene therapy treatments.
The PLASCAP® closure is a metal-free polypropylene cap with an integrated stopper, designed as a one-step press-fit solution for vial closure. It comes in ready-to-use, validated formats compatible with 13mm and 20mm crown vials. The new 6x8 nested tub configuration supports West 10ml nested CZ vials and selected nested vials with a 20mm crown.
West Pharmaceutical Services (NYSE: WST), a leader in injectable drug administration solutions, has announced its participation in the upcoming CJS 25th Annual "New Ideas for the New Year" Virtual Investor Conference. The company will be represented by Cindy Reiss-Clark (Sr. VP and Chief Commercial Officer), Chad Winters (VP of Finance and Chief Accounting Officer), and John Sweeney (VP of Investor Relations).
The presentation is scheduled for January 14, 2025, at 10:15 a.m. ET. Investors and interested parties can access the live audio webcast through the Investors section of West Pharmaceutical's website at www.westpharma.com.
West Pharmaceutical Services (NYSE: WST) has appointed Janet Haugen to its Board of Directors, expanding the board to 12 members. Haugen, 66, brings extensive financial and technological expertise from her previous role as Chief Financial Officer at Unisys , where she served for over 16 years. During her tenure, she led the company's transformation from a hardware-focused business to an IT services provider. Prior to Unisys, Haugen was a partner at Ernst & Young working with Fortune 500 companies. She currently serves on the boards of Bentley Systems, Juniper Networks, and CentralSquare Technologies. Haugen holds an Economics degree from Rutgers University and is a certified director of the National Association of Corporate Directors.
West Pharmaceutical Services (NYSE: WST) has announced its participation in three upcoming investor conferences in November 2024. The company will present at the UBS Global Healthcare Conference in California on November 12 at 3:30 PM PST, the Jefferies Healthcare Conference in London on November 19 at 1:00 PM GMT, and the Stephens Annual Investment Conference in Nashville on November 21 at 10:00 AM CST.
Live audio webcasts will be available on the company's website investor section, with replays accessible for approximately 90 days following each event.
West Pharmaceutical Services (NYSE: WST) reported third-quarter 2024 results with net sales of $746.9 million, showing a slight decline of 0.1%. The company's reported-diluted EPS was $1.85, down from $2.14 in the same period last year. Due to favorable currency movements, WST increased its full-year 2024 guidance, with net sales now expected between $2.875-2.905 billion and adjusted-diluted EPS range of $6.55-6.75. The Board approved a fourth-quarter dividend of $0.21 per share, marking the thirty-second consecutive annual increase. The Proprietary Products segment saw a 0.2% decline, while Contract-Manufactured Products grew by 0.4%.
West Pharmaceutical Services (NYSE: WST) announced its participation in the 2024 PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Phoenix, AZ. The company will showcase its expertise on industry challenges and trends in packaging and containment for injectable drugs.
Atul Patel, VP of Delivery Devices at West, highlighted the growing importance of injectables in the biologic drug segment and the need for adapting drug delivery packaging and devices. West will share insights through various posters and a presentation on leveraging primary container and device platforms to reduce risk and accelerate time-to-market for combination products.
The event features a speaking session by Gurmeet Singh on Enabling High-Volume Drug Delivery with a Platform Approach. Additionally, West will present posters on topics such as pre-filled syringe system performance at low temperatures, container closure integrity testing, vial adapter transfer devices, and visual impairment affordances in drug delivery systems.
FAQ
What is the current stock price of West Pharm Svcs (WST)?
What is the market cap of West Pharm Svcs (WST)?
What does West Pharmaceutical Services, Inc. specialize in?
Where is West Pharmaceutical Services headquartered?
What are the two main segments of West Pharmaceutical Services?
How much of West's revenue comes from international markets?
What recent products has West Pharmaceutical Services launched?
What are some of the key products offered by West Pharmaceutical Services?
How did West Pharmaceutical Services perform in the latest financial quarters?
What are West Pharmaceutical Services' long-term growth strategies?
How does West Pharmaceutical Services support its customers globally?
Where can I find more information about West Pharmaceutical Services?
